Repros Announces Registered Direct Offering of Approximately $11.1 Millon
Repros Therapeutics Inc.^ (Nasdaq: RPRX) today announced that it has entered into definitive agreements with certain institutional investors, including certain existing shareholders, to sell an aggregate of 2,463,538 shares of common stock, par value $0.001 per share in a registered direct offering for gross proceeds of approximately $11.1 million, before deducting placement agent's fees and estimated offering expenses. The investors have agreed to purchase the shares of Common Stock for a price of $4.50 per share.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.